Cover Image

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cel...

Full description

Saved in:
Bibliographic Details
Main Authors: Jagannath, Sundar (Author) , Lin, Yi (Author) , Goldschmidt, Hartmut (Author) , Reece, Donna (Author) , Nooka, Ajay (Author) , Senin, Alicia (Author) , Rodriguez-Otero, Paula (Author) , Powles, Ray (Author) , Matsue, Kosei (Author) , Shah, Nina (Author) , Anderson, Larry D. (Author) , Streetly, Matthew (Author) , Wilson, Kimberly (Author) , Le, Hoa Van (Author) , Swern, Arlene S. (Author) , Agarwal, Amit (Author) , Siegel, David S. (Author)
Format: Article (Journal)
Language:English
Published: 18 June 2021
In: Blood cancer journal
Year: 2021, Volume: 11, Pages: 1-9
ISSN:2044-5385
DOI:10.1038/s41408-021-00507-2
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41408-021-00507-2
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41408-021-00507-2
Get full text
Author Notes:Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, Donna Reece, Ajay Nooka, Alicia Senin, Paula Rodriguez-Otero, Ray Powles, Kosei Matsue, Nina Shah, Larry D. Anderson, Matthew Streetly, Kimberly Wilson, Hoa Van Le, Arlene S. Swern, Amit Agarwal and David S. Siegel
Description
Summary:Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748). In this retrospective study (KarMMa-RW), patient-level data from triple-class exposed RRMM patients were merged into a single data model and compared with KarMMa using trimmed stabilized inverse probability of treatment weighting. Endpoints included overall response rate (ORR; primary), rate of very good partial response or better (≥VGPR), progression-free survival (PFS), and overall survival (OS). Of 1949 real-world triple-class exposed RRMM patients, 190 received subsequent (index) line of therapy and met KarMMa eligibility criteria (Eligible RRMM cohort). With a median follow-up of 13.3 months in KarMMa and 10.2 months in Eligible RRMM, ORR, and ≥VGPR were significantly improved in KarMMa versus Eligible RRMM (ORR, 76.4% vs 32.2%; ≥VGPR, 57.9% vs 13.7%; both P < 0.0001) as were PFS (11.6 vs 3.5 months; P = 0.0004) and OS (20.2 vs 14.7 months; P = 0.0006). This study demonstrated that ide-cel significantly improved responses and survival compared with currently available therapies in triple-class exposed RRMM.
Item Description:Gesehen am 19.08.2021
Physical Description:Online Resource
ISSN:2044-5385
DOI:10.1038/s41408-021-00507-2

Similar Items